Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
Moderna Is Developing Two Different Omicron-Targeting Booster Shots - WSJ
Moderna completes FDA filing for bivalent COVID-19 booster vaccine, MR
/cloudfront-us-east-2.images.arcpublishing.com/reuters/TCSHY2P5Y5IZLADCIBDXST7MFQ.jpg "Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters")
Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters
Moderna is padding the case for its bivalent COVID-19 booster
U.S. government places $1.74B order for Moderna's new Covid-19 vaccine boosters - MedCity News
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant | bioRxiv
Moderna says updated booster generated 'significantly higher' neutralizing antibodies against BA.4/BA.5 subvariants - 6abc Philadelphia
Moderna on X: "ANNOUNCEMENT: The U.S. government has secured 66 million doses of our #COVID19 #vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA. Read
Moderna to advance two Omicron vaccine candidates against newer variants
Moderna: New booster protects better against variants - The Jerusalem Post
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant | bioRxiv
Moderna on X: "A Phase 2/3 trial for mRNA-1273.222 is currently underway. We have rapidly scaled manufacturing of mRNA-1273.222 to be ready, if authorized, to deliver doses in September. https://t.co/AQG4hfwNe6" / X
Health Canada grants authorisation for Moderna's Omicron-based booster
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Moderna says its Omicron shots provide better protection than original COVID-19 jab - National | Globalnews.ca
Moderna Submits Omicron-targeting Bivalent Booster Vaccine | RT
With 34 Vaccine Programs in Development, Moderna Eyes Global Launches | BioSpace
Moderna on X: "We have submitted a request for emergency use authorization (EUA) for our Omicron-targeting bivalent #COVID19 #vaccine, mRNA-1273.222, in children and adolescents 12 to 17 years of age to the
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /
Moderna says new booster effective against BA.4/BA.5 subvariants | CTV News
Moderna bivalent COVID-19 booster outperforms original against variants, company says
dinero.com.sv - Moderna receives FDA clearance for emergency use of Covid-19 booster vaccine
